{"prompt": "['Medical clearance to undergo a symptom-limited cardiopulmonary exercise test (CPET) and', 'vigorous aerobic and resistance exercise training.', 'Appendix 8: Certain medical questions with \"YES\\' responses require cardiologist', 'clearance or physician clearance to participate. See SOM for details.', 'Successfully pass the screening CPET by achieving:', 'Volitional exhaustion (RPE 9 using the Borg 0-10 RPE scale) in the absence of any', 'cardiorespiratory abnormalities.', 'If cardiorespiratory abnormalities are identified, please refer the patient to his', 'managing physician for further assessment and diagnosis.', 'Note: To assist practitioners with delivering valid CPET assessments, patients nearing', 'exhaustion should achieve a respiratory exchange ratio (RER) of >1.1.', 'RER is not a criteria of the test. This objective measure should only be used to assist', 'practitioners with patient management and decision-making.', \"Exercise Coordination Centre (ECC) review and approval of subject's screening bone scan/\", 'areas with bone metastases.', 'Subject is willing and able to use the technological aspects of the trial.', 'The subject is fluent in the language as designated by the institution at which he would be', 'enrolled.', '3.2 Exclusion Criteria', 'Previous radiographic or clinical progression (PSA progression is permitted) while on', 'treatment with abiraterone, enzalutamide, apalutamide, or a combination.', 'Previously identified small cell neuroendocrine tumours or pure small cell carcinoma of the', 'prostate, based on a prior biopsy of the prostate.', 'Brain metastases (brain imaging is not required)', 'Previous and/or concurrent treatment with other anti-cancer treatments is permitted. Patients', 'are allowed to be treated with chemotherapy during the duration of the trial. Patients who', 'have received chemotherapy as part of initial androgen deprivation therapy for metastatic', 'castration sensitive disease are eligible.', 'Currently receiving experimental treatment with non-approved drugs at the time of enrolment.', 'Patients must undergo a 28-day washout between last dose and screening CPET.', 'Poorly controlled hypertension. During screening >2/3 of readings must be < 160/90,', 'regardless of whether on a regimen of anti-hypertensive therapy or not.', 'If patient is currently taking hypertensive medication(s)/therapy, please indicate', 'medication and include in the Treatment and Concomitant Medications Log (SOM:', 'Appendix 11).', 'Current congestive heart failure (New York Heart Association Class II, III or IV)', 'Recent serious cardiovascular events (within 12 months) including, but not limited to, transient', 'ischemic attack (TIA), cerebrovascular accident (CVA), or myocardial infarction (MI).', 'Medical condition such as uncontrolled infection or cardiac disease that, in the opinion of the', 'physician, would make this protocol unreasonably hazardous for the patient.', 'Patients with a currently active second malignancy other than non-melanoma skin cancer.', 'Patients are not considered to have a currently active malignancy if they have completed', 'necessary therapy and are considered by their physician to be at <30% risk of relapse at time', 'of assessment.', 'Psychiatric illness, which would prevent the patient from giving informed consent or adhering', 'to the study protocol.', 'Serious or non-healing wound, ulcer, or bone fracture.', 'Known spinal cord compromise or instrumentation due to metastatic disease in the mCRPC', 'state. Radiation therapy for metastatic disease is allowed.', 'Peripheral neuropathy >grade 3.', 'Men participating in vigorous aerobic exercise for more than 60 minutes per week or structured', 'INTERVAL Protocol Version 4.0, 19 April 2018', '14']['resistance exercise two or more days per week (seek ECC approval before exclusion).', 'Experiences shortness of breath, chest discomfort, or palpitations when performing activities', 'of daily living (patient with these symptoms can participate in the study with cardiologist', 'clearance)', 'Ongoing restriction of physical activity with physician documentation', 'Has chest pain brought on by physical activity (patient can participate in the study with', 'cardiologist clearance)', 'Has developed chest pain in the past month (patient can participate in the study with', 'cardiologist clearance)', \"Moderate-to-severe bone pain (i.e., National Cancer Institute's Common Terminology Criteria\", 'for Adverse Events grade 2-3 bone pain).', 'Men who do not complete the baseline lifestyle and quality-of-life questionnaires and 3-days', 'of diet diaries or country-specific FFQ will not be eligible', '4.0 SCREENING, RANDOMISATION, STRATIFICATION, BLINDING', '4.1 Informed Consent', 'All patients must willingly consent after being informed of the procedures to be followed, the experimental', 'nature of the intervention, alternatives, potential benefits, side effects, risks, and discomforts. Human', 'protection committee approval of this protocol and its consent form are required. Informed consent is required', 'before any study-specific procedure is performed. Patients who sign the study consent form should be', 'entered into the screening database.', '4.2 Screening', 'Patients who are potentially eligible for GAP4 and sign the study Informed Consent should be given a site', 'specific screening ID, and entered into the database. Participants will continue to be screened for the trial', 'until 866 participants have been randomised.', '4.3 Enrolment', 'A physician must determine whether a patient is eligible for GAP4 based on the inclusion criteria. The', 'screening CPET must occur within 14 days of Day 1, Cycle 0 (Baseline). Prior to randomisation, approved', 'GAP4 institutions must have Site Coordination Centre (SCC) approval and enter all of the following', 'information into the following online database forms:', 'Consenting', 'Subject Identification', 'Patient-completed Demographics, Exercise Screening, and Questionnaires Parts 1-4', 'Physician Clearance Form', 'Eligibility for CONSORT Reporting and Signed Eligibility Criteria Checklist', 'When the patient successfully completes screening procedures and is eligible for enrolment, a patient', 'identification number (separate from the patient screening ID) will be assigned. Participants will continue to', 'be enrolled onto the trial until 866 participants have been randomised.', '4.4 Randomisation', 'After SCC approval, patients will be randomised in a 1:1 ratio to intervention (Supervised Exercise/SE) group', 'or control (Self-directed Exercise/SDE) group, stratifying by treatment status at time of randomisation and', 'study site. Randomisation will be performed through the study database but maintaining concealment from', 'patients and recruiting staff, upon which time a Study ID will be assigned to the subject.', '4.5 Stratification', 'Patients will be stratified by study site and treatment status at the time of registration: 1) Patients who are', 'treatment na\u00efve or stable on Abiraterone/Enzalutamide/Apalutamide or 2) Patients who are on/received first', 'line chemo OR progressing on first line Abiraterone/Enzalutamide/Apalutamide, Patients treated with radium-', '223 will need medical monitoring review for correct stratification placement. Previous and/or concurrent', 'treatment with other anti-cancer therapies is permitted. Patients who have previously received sipuleucel-t,', 'meet study eligibility, and are not on the treatments listed above, are not considered on treatment. Patients', 'INTERVAL Protocol Version 4.0, 19 April 2018', '15']\n\n###\n\n", "completion": "END"}